belantamab (GSK2857914) / GSK - LARVOL DELTA

Matching-Adjusted Indirect Treatment Comparison of Teclistamab with Daratumumab (Tec-Dara) vs Belantamab with Bortezomib and Dexamethasone (Bvd) for Early-Line Relapsed/Refractory Multiple Myeloma (IMS 2026) - P3 | "Introduction: In the phase 3 MajesTEC-3 study (NCT05083169), Tec-Dara significantly improved PFS/OS vs Dara-based standard-of-care (SoC) in patients (pts) with RRMM and 1-3 prior lines of therapy (pLOTs). Tec-Dara showed clinical and statistically significant PFS/OS improvement, with a 78%/52% risk reduction, respectively, compared with BVd in the base-case MAIC. Moreover, Tec-Dara more than doubled the rate of ≥CR. Notably, MajesTEC-3 had a highly lenalidomide-refractory population (84% vs 34% in DREAMM-7); however, Tec-Dara’s comparative benefit persisted after robust, conservative MAIC adjustment, highlighting Tec-Dara’s ability to elicit deep and durable responses, supporting its use as a highly effective, fully immunotherapy-based, steroid-sparing SoC regimen in RRMM as early as first relapse."

Hematological Malignancies • Multiple Myeloma

Matching-Adjusted Indirect Treatment Comparison of Teclistamab Monotherapy (Tec) vs Belantamab with Pomalidomide and Dexamethasone (Bpd) for Early-Line Relapsed or Refractory Multiple Myeloma (RRMM) (IMS 2026) - P3 | "In DREAMM-8 (NCT04484623), belantamab mafodotin, a BCMA-directed ADC, plus Pd (BPd) also improved PFS vs PVd in early-line RRMM; 24% were anti-CD38 refractory. Tec monotherapy showed superior PFS benefit and doubled the likelihood of achieving ≥CR, an important indicator of durable responses, vs BPd in pts with early-line RRMM per anchored MAIC. Although MajesTEC-9 included a heavily anti-CD38 refractory population, Tec’s comparative benefit persisted after MAIC adjustment, supporting Tec as a highly effective standard-of-care therapy as early as first relapse, regardless of anti-CD38 exposure/refractory status."

Monotherapy • Hematological Malignancies • Multiple Myeloma

Impact of Prior Anti-Bcma Antibody-Drug Conjugate Exposure and High-Risk Cytogenetics on Outcomes with BCMA Bispecifics in Relapsed/Refractory Multiple Myeloma: A Single Centre Real-World Analysis (IMS 2026) - "Median PFS was 9.8 months, with no difference between teclistamab and elranatamab (HR 1.05, p=0.87). Fourteen patients (25%) had prior belantamab mafodotin exposure and all were ADC-refractory before TCE treatment...Prior belantamab exposure did not adversely affect PFS following TCE therapy (HR 1.29, 95%CI 0.61–2.69; p=0.5); 12-month PFS was 48% versus 53% in belantamab-exposed versus non-exposed patients, respectively... In this real-world RRMM cohort with prolonged follow-up, prior anti-BCMA ADC exposure did not impair outcomes of subsequent BCMA-targeting TCE therapy. Conversely, extramedullary disease and cumulative HRCA burden remained associated with inferior outcomes, supporting their continued prognostic relevance in the bispecific antibody era."

ADC • Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma

Deep Sustained Response to Belantamab Mafodotin Despite Reversible Grade 4 Ocular Toxicity in Relapsed/Refractory Multiple Myeloma in the Brazilian Public Health System (IMS 2026) - "Belantamab,bortezomib and dexamethasone (Bela-Vd) and achieved a deep and sustained response after only two infusions, despite developing fully reversible grade 4 ocular toxicity. This case highlights the remarkable antitumor activity of belantamab even after limited exposure, including in the setting of relapsed disease. The occurrence of KVA4 represents a clinically significant treatment-limiting complication. Nevertheless, the clinical course observed in this patient reinforces that ocular toxicity may be reversible even in severe cases."

Hematological Malignancies • Multiple Myeloma • Ophthalmology

Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma (IMS 2026) - "DREAMM-7 compared belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone. DREAMM-8 compared belantamab mafodotin, pomalidomide, and dexamethasone versus pomalidomide, bortezomib, and dexamethasone... Belantamab mafodotin-containing triplets significantly improve PFS compared with active-control triplets in RRMM, with consistent benefit observed across two pivotal phase III studies. These findings support belantamab-based triplets as clinically important off-the-shelf BCMA-directed options in RRMM while emphasizing the importance of careful ocular toxicity monitoring and mitigation strategies."

Hematological Malignancies • Multiple Myeloma

Belantamab Mafodotin Plus Vd in Relapsed/Refractory Multiple Myeloma - an Optimized Regimen Mitigates Ocular Adverse Events Without Compromising Clinical Efficacy: A Czech Multicenter Phase 2 Study (IMS 2026) - P1/2 | "The aim was to evaluate whether a lower dose of belamaf (1.9 mg/kg) administered less frequently (Q8W) in combination with bortezomib and dexamethasone in patients (pts) with multiple myeloma in their second or higher line of therapy could achieve comparable efficacy with decreased toxicity compared with the standard belamaf dosing (2.5 mg/kg Q3W). In the study, the primary endpoints were successfully achieved: the incidence of KVA gr.3 was substantially decreased, while efficacy was maintained. These results support modification of the original belantamab dosing schedule to mitigate ocular adverse events without compromising clinical efficacy. Despite the inclusion/exclusion criteria mirrored DREAMM-7 study, direct comparison with any DREAMM study is limited by an older, more heavily pretreated cohort (median of 3 prior LOT)."

Adverse events • Clinical • P2 data • Hematological Malignancies • Multiple Myeloma • Ophthalmology

Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. (PubMed, Pharmacoecon Open) - P3 | "The threshold price of belantamab for BVd to be cost effective over DVd is US$5.73/mg at a WTP threshold of twice China's GDP per capita, indicating a need for a very substantial price reduction of approximately 98% from the US list price. This estimate provides evidence-based reference for future national price negotiation and reimbursement decisions in China."

HEOR • Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology

Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database. (TCT-ASTCT-CIBMTR 2024) - "The predominant subsequent therapy was non cytotoxic (ex-Dara, Selinexor) -33%, followed by IET-29%, targeted therapy at 5.6%, cytotoxic chemo at 15% and XRT only in 4.9%. BCMA Bispecific was the predominant subsequent IET used at 65% followed by belantamab at 20%... In this large retrospective multicenter cohort looking at post relapse outcomes of ide-cel, the median PFS 1 and PFS 2 was 60 and 47 days. IEC therapies were associated with better median PFS even immediately after ide-cel therapy and should be considered as the first choice if available."

Hematological Malignancies • Multiple Myeloma • Oncology

Belantamab Mafodotin Combinations in Relapsed or Refractory Multiple Myeloma: Re-Emergence of B-Cell Maturation Antigen Antibody-Drug Conjugate Therapy Across Clinical Trials (SOHO 2026) - "Recent trials evaluated belantamab-containing triplets against established standards, with ocular toxicity remaining a key management concern...In DREAMM-7, 494 patients were randomized to belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone...In DREAMM-8, 302 patients were randomized to belantamab mafodotin, pomalidomide, and dexamethasone vs pomalidomide, bortezomib, and dexamethasone... Belantamab mafodotin combinations demonstrated substantial efficacy across relapsed or refractory MM trials, including randomized progression-free survival benefit and deeper responses vs standard triplets. These findings support the reemergence of BCMA antibody-drug conjugate therapy in combination regimens, while emphasizing ocular toxicity mitigation as central to clinical implementation. BCMA: B-cell maturation antigen, CI: confidence interval, HR: hazard ratio, MM: multiple myeloma, PRISMA: Preferred Reporting Items for Systematic..."

ADC • Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma (SOHO 2026) - "Other belantamab studies were excluded because they evaluated monotherapy, earlier-phase combinations, or regional expansion cohorts or were duplicate updated analyses, rather than independent phase 3 randomized triplet comparisons. Interventions: DREAMM-7 compared belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone. DREAMM-8 compared belantamab mafodotin, pomalidomide, and dexamethasone versus pomalidomide, bortezomib, and dexamethasone... Belantamab mafodotin-containing triplets significantly improve PFS in patients with RRMM, compared with active-control triplets, with consistent benefit observed across two pivotal phase 3 studies. These findings support belantamab-based triplets as clinically important off-the-shelf BCMA-directed options in RRMM, while emphasizing the importance of careful ocular toxicity monitoring and mitigation strategies. BCMA: B-cell maturation antigen, CI: confidence interval, MRD: measurable..."

Hematological Malignancies • Multiple Myeloma • Oncology

Maintenance Therapy with Belantamab, Pomalidomide and Dexamethasone in High-risk Myeloma Patients: A Phase 2 Study with a Safety Run-in - Interim Analysis (IMS 2025) - P2 | "In pts with high-risk myeloma, BPd maintenance deepened responses, with MRD negativity (10-5) attained in 80% of pts. The extended dosing schedule of belantamab 1.9 mg/kg every 12 weeks is not associated with higher grade toxicities and had proven efficacy in this setting. The current results support the exploration of BPd maintenance in future high-risk studies."

Clinical • Late-breaking abstract • P2 data • Cardiovascular • CNS Disorders • Cough • Hematological Malignancies • Inflammation • Insomnia • Multiple Myeloma • Ophthalmology • Pneumonia • Respiratory Diseases • Sleep Disorder

Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial (IMS 2025) - P1 | "Introduction: Belantamab mafodotin (belamaf) is a B-cell maturation antigen (BCMA)–targeted monoclonal antibody (mAb) conjugated with a monomethyl auristatin F (MMAF) payload. Belantamab had a favorable safety profile, with no DLTs, TRAEs leading to discontinuation, or grade ≥2 corneal events associated with belantamab. Encouraging preliminary clinical activity was observed, with durable responses occurring across dose levels in this heavily pretreated, triple class−exposed population. These findings support the potential of belantamab to provide clinical activity with an acceptable safety profile."

First-in-human • P1/2 data • Anemia • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Ophthalmology

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma (ASH 2024) - "The incidence and severity of CRS and NT, the average number of days in the hospital and in the ICU, the need for tocilizumab, anakinra, steroids, the incidence and severity of cytopenias, and the need for stem cell boosts did not differ significantly between those with and without prior exposure to belantamab (p > 0.05). Specifically, patients who respond to belantamab exhibit inferior outcomes with ide-cel compared to those not achieving a partial or better response to belantamab. With the potential re-approval of belantamab and the increasing availability of BCMA CAR T-cell therapy, understanding the impact of previous exposure to BCMA-directed therapies is crucial for optimizing treatment selection for these patients."

Clinical • Anemia • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Ophthalmology • Thrombocytopenia

DynaMMic-2: A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database. (PubMed, J Oncol Pharm Pract) - "We conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) to identify CAEs associated with ADCs for hematologic malignancies and assess high-risk subpopulations.MethodsWe analyzed five ADCs: gemtuzumab ozogamicin, inotuzumab ozogamicin, polatuzumab vedotin, loncastuximab tesirine, and belantamab mafodotin...Disproportionality analysis used four metrics: reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and Empirical Bayes Geometric Mean (EBGM), with signals defined as significant across all.ResultsCAEs represented 3.2% of adverse events (AEs) for gemtuzumab, 2.0% for polatuzumab, 0.96% for inotuzumab, and 1.3% for belantamab...These results support the need for drug labeling and cardiac monitoring in high-risk groups. Prospective studies should inform evidence-based recommendations regarding ADC administration and cardiotoxicity risk."

Adverse events • Journal • Real-world evidence • Cardiovascular • Heart Failure • Hematological Disorders • Hematological Malignancies • Myocardial Ischemia • Oncology

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma. (PubMed, Future Oncol) - "While bela-maf failed to show efficacy as monotherapy for relapsed/refractory myeloma in its initial phase 3 trial, it subsequently showed significant improvement in progression-free survival in combination with either bortezomib/dexamethasone (BVd, DREAMM-7) or pomalidomide/dexamethasone (BPd, DREAMM-8) resulting in updated regulatory approval...Bela-maf-induced ocular toxicity requires close ophthalmology monitoring and may be partially mitigated by reducing the dose or frequency of bela-maf, and further data are needed to optimize dosing strategies. Herein, we review the pharmacology, clinical efficacy, and unique safety precautions related to belantamab mafodotin, as well as highlight ongoing studies of its use in earlier lines of therapy and in combination with other anti-myeloma agents."

Journal • Review • Dry Eye Disease • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Ophthalmology

DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov) - P1/2 | N=123 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Dec 2029 ➔ Aug 2028 | Trial primary completion date: Dec 2029 ➔ Aug 2028

Monotherapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy. (ASCO 2026) - "MM patients aged ≥18 years who had received prior BDT (Ide-cel, Cilta-cel, Teclistamab, Elranatamab) were selected...Treatment patterns showed a heavily pretreated population: proteasome inhibitors (bortezomib 44.7%), IMiDs (lenalidomide 65%, pomalidomide 56%), anti-CD38 therapy (daratumumab 49%), CAR T (20%), autologous stem cell transplant (44.3%), belantamab (5.7%), elranatamab (6%), and teclistamab (74%)... This real-world study showed no significant difference in mortality, toxicities, infectious or healthcare outcomes between talquetamab and BDT in RRMM patients with prior BCMA exposure. This suggests that antigen escape is less common than anticipated. While these results need to be further evaluated in prospective studies, future research should focus on outcomes based on timing or type of prior BCMA therapy, biomarker-driven treatment selection, and optimal sequencing based on resistance mechanisms."

Bispecific • Clinical • IO biomarker • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

OCULAR TOXICITIES OF BELANTAMAB MAFODOTIN MONOTHERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2026) - "Future prospective studies should refine dose optimization strategies and clarify the positioning of belantamab among emerging BCMA-targeted therapies. Table 1- Pooled Outcomes of Belantamab Mafodotin for Multiple Myeloma stratified by dosage"

Monotherapy • Retrospective data • Review • Hematological Malignancies • Multiple Myeloma • Ophthalmology

MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM ANALYSIS (EHA 2026) - P2 | "(%) 4 (21) Caucasian, no (%) 10 (53) Hispanic, no (%) 4 (21) Other, no (%) 1 (5) R-ISS, no (%) Stage I 3 (16) Stage II 11 (58) Stage III 3 (16) Unknown 2 (11) Cytogenetic risk category, no (%) Standard-risk 8 (42) High-risk 10 (53) Unknown 1 (5) Induction therapy, no (%) D-VRd 9 (47) D-KRd 4 (21) D-Rd 1 (5) D-Vd 1 (5) VRd 4 (21) R-ISS, Revised International Staging System; D-VRd, daratumumab, bortezomib, lenalidomide, dexamethasone; D-KRd, daratumumab, carfilzomib, lenalidomide, dexamethasone; D-Rd, daratumumab, lenalidomide, dexamethasone; D-Vd, daratumumab, bortezomib, dexamethasone; VRd, bortezomib, lenalidomide, dexamethasone Summary/Conclusion Belantamab mafodotin plus lenalidomide maintenance shows promising MRD ‑ negative rates with predictable, reversible ocular toxicity. Ocular events were frequent but limited to grade 1–2. The every ‑ 12 ‑ week belantamab schedule offers an effective, lower ‑ burden dosing approach for patients and providers."

Clinical • Breast Cancer • Dry Eye Disease • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Ophthalmology • Pneumonia • Respiratory Diseases • Solid Tumor

DE-ESCALATED DOSING OF BELANTAMAB MAFODOTIN PLUS VD REDUCES THE INCIDENCE OF OCULAR EVENTS WHILE MAINTAINING EFFICACY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A CZECH MULTICENTER PHASE 2 STUDY (EHA 2026) - P1/2 | "The aim was to evaluate whether a lower dose of belamaf (1.9 mg/kg) administered less frequently (Q8W) in combination with weekly bortezomib and dexamethasone in patients (pts) with multiple myeloma after ≥1 line of therapy could achieve comparable ef<cacy with improved toxicity compared with the standard dosing regimen (2.5 mg/kg Q3W)...These findings support modification of the original belantamab dosing schedule to mitigate ocular adverse events without compromising clinical efficacy. Despite the inclusion/exclusion criteria mirrored DREAMM-7 study, direct comparison with any DREAMM study is limited by an older, more heavily pretreated cohort (median of 3 prior LOT). Funding and product were provided by GSK."

Clinical • P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hepatology • Infectious Disease • Multiple Myeloma • Ophthalmology

REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN–BASED CONTAINING REGIMEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A EMN LAZIO WORKING GROUP EXPERIENCE. (EHA 2026) - "Background Belantamab mafodotin–containing regimen with bortezomib- dexamethasone (BVd) or pomalidomide-dexamethasone (BPd) represent a promising therapeutic strategy for relapsed/refractory multiple myeloma (RRMM)...Methods We retrospectively and prospectively reviewed data of thirty-two pts who received belantamab-containing regimen for RRMM in 9 centers of EMN Lazio (Italy) between 2025 and 2026...Figure: Overall survival according to depth of response (CR/VGPR vs other responses). Exploratory analysis suggests improved outcomes among patients achieving deeper responses."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Ophthalmology

GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: PETHEMA Foundation

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • B2M

Early intravenous immunoglobulin use in multiple myeloma patients treated with talquetamab: Effect on risk of infections and mortality. (ASCO 2026) - "Propensity score matching was performed which included comorbidities, demographics, prior therapies (PIs, ImIDs, anti-CD38 abs, other BiTEs, belantamab, SCTx and CAR T), lab markers of disease severity, IgG levels, EM disease and plasma cell leukemia. Early IVIG administration following talquetamab initiation was associated with reduced infection risk and improved survival in a large real-world cohort. These findings support consideration of early IVIG as part of routine supportive care for patients receiving talquetamab."

Clinical • IO biomarker • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres. (PubMed, Br J Haematol) - No abstract available

Clinical data • Journal • Ophthalmology